The lancet oncology
-
The lancet oncology · Mar 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Treatment options are limited for patients with thymic carcinoma. These aggressive tumours are not typically associated with paraneoplastic autoimmune disorders, and strong PD-L1 expression has been reported in thymic epithelial tumours. We aimed to assess the activity of pembrolizumab, a monoclonal antibody that targets PD-1, in patients with advanced thymic carcinoma. ⋯ Merck & Co.